Cargando…

Development of the neurotrophic keratopathy questionnaire: qualitative research

BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Lindsey T., McCormack, Julie, Grobeiu, Ioana, Wiklund, Ingela, Kimel, Miriam, Van Nooten, Floortje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198680/
https://www.ncbi.nlm.nih.gov/pubmed/32367451
http://dx.doi.org/10.1186/s41687-020-00192-y
_version_ 1783529034340106240
author Murray, Lindsey T.
McCormack, Julie
Grobeiu, Ioana
Wiklund, Ingela
Kimel, Miriam
Van Nooten, Floortje
author_facet Murray, Lindsey T.
McCormack, Julie
Grobeiu, Ioana
Wiklund, Ingela
Kimel, Miriam
Van Nooten, Floortje
author_sort Murray, Lindsey T.
collection PubMed
description BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patients and assess the overall comprehension, relevance, and content validity of a new questionnaire. METHODS: This was a cross-sectional, qualitative study conducted with NK patients with varying levels of disease severity, recruited from one clinical site. One-on-one interviews using concept elicitation and cognitive interviewing techniques were conducted. RESULTS: Fourteen NK patients participated; 64.3% were female (n = 9), mean age was 65.7 ± 13.3, and 14.3% (n = 2), 21.4% (n = 3), and 64.3% (n = 9) were classified as Mackie stage I, stage II, or stage III, respectively. Participants reported 24 concepts, including: redness (n = 12, 86%), sensitivity to light (n = 11, 79%), general discomfort (n = 9, 64%), dry eye (n = 9, 64%), reduced visual acuity (n = 9, 64%), blurred vision (n = 8, 57%), and eye fatigue (n = 8, 57%). No new concepts were reported after the 13th interview. The most frequently reported impacts included frustration (n = 10, 71%), driving impairment (n = 8, 57%), reading impairment (n = 7, 50%), difficulty watching television (n = 7, 50%), and concern with potentially losing their eyesight due to NK (n = 6, 43%). Participants provided positive feedback on the draft NK Questionnaire (NKQ) and felt that it was comprehensive and relevant to their experience with NK. Additionally, the recall period, instructions, item concepts, and response options were well-understood by participants. Minor revisions were made to the tool for consistency (i.e., the timeframe “in the past 7 days” was added to items 12–14); item 14 was modified to include “how often”; examples were added to item 9. CONCLUSIONS: The results of the concept elicitation portion of the qualitative study support the content validity of the draft NKQ. The clinically significant concepts identified in the literature and raised during concept elicitation are included as items in the questionnaire. Further assessment of the psychometric properties should be conducted in support of this new tool to measure the effect of new treatments on symptoms and impacts associated with NK.
format Online
Article
Text
id pubmed-7198680
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71986802020-05-06 Development of the neurotrophic keratopathy questionnaire: qualitative research Murray, Lindsey T. McCormack, Julie Grobeiu, Ioana Wiklund, Ingela Kimel, Miriam Van Nooten, Floortje J Patient Rep Outcomes Research BACKGROUND: Neurotrophic keratopathy/keratitis (NK) is a rare disease of the cornea that can lead to anatomical loss of the eye. Little is known about the NK experience from the patients’ perspective. The objectives of this study were to examine the symptomatic experience and impacts of NK on patients and assess the overall comprehension, relevance, and content validity of a new questionnaire. METHODS: This was a cross-sectional, qualitative study conducted with NK patients with varying levels of disease severity, recruited from one clinical site. One-on-one interviews using concept elicitation and cognitive interviewing techniques were conducted. RESULTS: Fourteen NK patients participated; 64.3% were female (n = 9), mean age was 65.7 ± 13.3, and 14.3% (n = 2), 21.4% (n = 3), and 64.3% (n = 9) were classified as Mackie stage I, stage II, or stage III, respectively. Participants reported 24 concepts, including: redness (n = 12, 86%), sensitivity to light (n = 11, 79%), general discomfort (n = 9, 64%), dry eye (n = 9, 64%), reduced visual acuity (n = 9, 64%), blurred vision (n = 8, 57%), and eye fatigue (n = 8, 57%). No new concepts were reported after the 13th interview. The most frequently reported impacts included frustration (n = 10, 71%), driving impairment (n = 8, 57%), reading impairment (n = 7, 50%), difficulty watching television (n = 7, 50%), and concern with potentially losing their eyesight due to NK (n = 6, 43%). Participants provided positive feedback on the draft NK Questionnaire (NKQ) and felt that it was comprehensive and relevant to their experience with NK. Additionally, the recall period, instructions, item concepts, and response options were well-understood by participants. Minor revisions were made to the tool for consistency (i.e., the timeframe “in the past 7 days” was added to items 12–14); item 14 was modified to include “how often”; examples were added to item 9. CONCLUSIONS: The results of the concept elicitation portion of the qualitative study support the content validity of the draft NKQ. The clinically significant concepts identified in the literature and raised during concept elicitation are included as items in the questionnaire. Further assessment of the psychometric properties should be conducted in support of this new tool to measure the effect of new treatments on symptoms and impacts associated with NK. Springer International Publishing 2020-05-04 /pmc/articles/PMC7198680/ /pubmed/32367451 http://dx.doi.org/10.1186/s41687-020-00192-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Murray, Lindsey T.
McCormack, Julie
Grobeiu, Ioana
Wiklund, Ingela
Kimel, Miriam
Van Nooten, Floortje
Development of the neurotrophic keratopathy questionnaire: qualitative research
title Development of the neurotrophic keratopathy questionnaire: qualitative research
title_full Development of the neurotrophic keratopathy questionnaire: qualitative research
title_fullStr Development of the neurotrophic keratopathy questionnaire: qualitative research
title_full_unstemmed Development of the neurotrophic keratopathy questionnaire: qualitative research
title_short Development of the neurotrophic keratopathy questionnaire: qualitative research
title_sort development of the neurotrophic keratopathy questionnaire: qualitative research
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198680/
https://www.ncbi.nlm.nih.gov/pubmed/32367451
http://dx.doi.org/10.1186/s41687-020-00192-y
work_keys_str_mv AT murraylindseyt developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch
AT mccormackjulie developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch
AT grobeiuioana developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch
AT wiklundingela developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch
AT kimelmiriam developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch
AT vannootenfloortje developmentoftheneurotrophickeratopathyquestionnairequalitativeresearch